We investigated the effects of transdermal 17␤-estradiol, combined with standard antihypertensive therapy, on the modification of the cardiovascular risk profile in hypertensive postmenopausal women. In a randomized, double-blind, placebocontrolled study, we enrolled 200 postmenopausal women with mild to moderate hypertension. Patients received 17␤-estradiol (50 g/day, transdermal) and norethisterone acetate (2.5 mg/ day, orally) or placebo. At baseline serum total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, glucose, and fibrinogen plasma levels were measured and all subjects underwent complete M-mode and 2-D echocardiograms, which were repeated after 6, 12, and 18 months of hormonal replacement therapy. Compared with placebo, all values decreased significantly except for HDL cholesterol. In both groups, no modifications were observed in echocardiographic parameters, except for left ventricular mean diastolic and systolic wall thickness and left ventricular mass index, which showed a significant decrease in both groups. The reduction was greater in the treated group; the percentage of patients with left ventricular hypertrophy was 46% before randomization and 17.2% after 18 months of treatment (P < .0001), whereas in group II the percentage was 48% at baseline and 31.5% after 18 months (P < .05).
H ypertension is a highly prevalent major risk factor for atherosclerosis, including coronary artery disease, heart failure, stroke, and peripheral artery disease. 1 Postmenopausal women represent the largest category of women at risk for hypertension. 2, 3 Women have a lower incidence of hypertension than men in early adult life but their blood pressures increase more dramatically with age, reaching or exceeding those of men beyond the age of 50 years. 4 In the Framingham Study cohort, an average 20 mm Hg systolic and 10 mm Hg diastolic increment increase in blood pressure was reported in women from 30 to 65 years of age. 5 Estrogen-related protection, which is physiologically lost with aging, can be partially replaced by therapeutic interventions: the oral administration of 17␤-estradiol improves the cardiovascular risk profile in postmenopausal women, 6, 7 and observational stud-ies have shown its protective effect on the cardiovascular system. 8 -11 Transdermal application has been proposed as an alternative and effective route of administration, with the advantage that natural estrogen is used. [12] [13] [14] Given that transdermal estrogen administration is widely used by the European female population, we designed a double-blind, randomized, placebo-controlled study to evaluate the effects of transdermal 17␤-estradiol, combined with standard antihypertensive therapy, on the modification of cardiovascular risk profile in hypertensive postmenopausal women. 15 ) who attended our ambulatory clinic. In accordance with the World Health Organization criteria, menopause was defined by the absence of menstruation for at least 12 months and by follicle-stimulating hormone blood levels higher than 40 IU/L and 17␤-estradiol levels lower than 110 pmol/L. 16 Hypertension was diagnosed by two consecutive measurements at an interval of 1 week after an initial high reading; blood pressure measurements were performed according to the American Society of Hypertension recommendations. 17 Patient history, physical examination, 12-lead electrocardiogram, and echocardiogram were used to exclude past or current heart disease. All hypertensive women were advised to modify their lifestyle habits according to the recommendations of the JNC V 15 : reducing salt intake, losing weight (if overweight), moderate alcohol consumption, smoking cessation, and engaging in physical activity. If these measures were not able to reduce blood pressure values, pharmacologic therapy was initiated. Therapies were assigned to maintain systolic blood pressure less than 140 mm Hg and diastolic blood pressure less than 90 mm Hg. This phase of antihypertensive therapy adjustment lasted 6 months; during this period patients were controlled every 4 weeks.
MATERIALS AND METHODS

Study Design
Patients with blood pressure values less than 140/90 mm Hg for at least three consecutive measurements were randomly assigned, in a double-blind fashion, to receive 17␤-estradiol or placebo (Figure 1 ). Exclusion criteria are listed in Table 1 . 17␤-estradiol was administered in the form of self-adhesive cutaneous patches, providing a cutaneous absorption rate of 50 g/24 h. The placebo patches were identical in appearance, and all patches were changed twice weekly. Patients treated with estrogen received norethisterone acetate (2.5 mg/day, orally) for 12 days of each 28-day cycle, whereas patients not treated with estrogen received placebo. In case of untoward effects, the dose of estrogen was reduced (from 50 to 25 g/ day) and if they persisted, the patient was dropped from the study.
At baseline in all patients serum total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, glucose, and fibrinogen plasma levels were sampled and Laboratory Analysis Biochemical blood tests included: total serum cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, glucose, and fibrinogen plasma levels, all sampled in subjects who had fasted for at least 12 h. Total cholesterol, and HDL and LDL cholesterol were measured with an enzymatic method (CHOD PAP, Merck KGaA, Darmstadt, Germany). 18 Enzyme photometric methods were used for triglycerides (GPO PAP, Merck KGaA, Darmstadt, Germany) 19 and glucose plasma dosage (Gluc-DH, Merck KGaA, Darmstadt, Germany). 20 Serum fibrinogen was measured chronometrically in accordance with the Von Clauss method (Fibrinomat, bioMerieux sa, Lyon, France).
21
Echocardiographic Examination The M-mode echocardiographic study of the left ventricle was performed under cross-sectional control with a commercially available machine (Acuson 128 XP/10c, Acuson Inc., Mountain View, CA), according to the American Society of Echocardiography recommendations. 22 Wall thickness (WT) was expressed as mean WT, which represents the mean value of septal and posterior WT. Left ventricular systolic fractional shortening (FS, %) was calculated using the following formula: [end diastolic diameter (EDD) Ϫ end systolic diameter (ESD)/ EDD]. Left ventricular mass (LVM, g) was calculated using the formula introduced by Devereux and . 24 The variability (mean absolute difference) between measurements within two observers was measured for LVM (28 g), FS (2.5 %), EDD (2.7 mm), ESD (2.4 mm), and mean diastolic WT (2 mm).
Statistical Analysis
The continuous variables were expressed as mean Ϯ 1 standard deviation and the categorical variables as percentages. The two groups were compared using the Student's t test for unpaired data and the 2 test with Yates correction for continuity, when appropriate. Baseline values and those 
RESULTS
Patients Among 200 postmenopausal women with primary mild to moderate hypertension, 100 (group I) were randomly assigned to treatment with transdermal 17␤-estradiol plus norethisterone acetate and 100 (group II) to placebo. Baseline demographic, clinical, echocardiographic, and biochemical parameters were compared between the groups and no significant differences were found ( Table 2 ). After 18 months of treatment 17␤-estradiol plasma levels increased from 54 Ϯ 31 pmol/L to 392 Ϯ 63 pmol/L in group I (P Ͻ .0001), whereas in group II it did not vary significantly (from 60 Ϯ 23 pmol/L to 65 Ϯ 25 pmol/L; P ϭ ns). The transdermal estrogen therapy with 50 g/day of 17␤-estradiol was well tolerated: in only 8 of 100 treated patients did we have to reduce the dosage of 17␤-estradiol to 25 g/day: for vaginal bleeding (two cases) or for breast tenderness (six cases). None of the patients had to suspend estrogen therapy for untoward effects. The antihypertensive treatment regimen is shown in Table 3 . Between the two groups there was no difference in the dropout rate: 7% in group I and 8% in group II (P ϭ ns). During the follow-up, no acute cardiovascular and cerebrovascular events or deaths were recorded.
Effects of Treatment With 17␤-Estradiol
After 18 months of therapy with transdermal 17␤-estradiol total cholesterol, LDL cholesterol, triglycerides, glucose, and fibrinogen plasma levels decreased significantly (Table 4) ; the reduction was recorded after 6 months of treatment as well as after 12 and 18 months. In the placebo group, no significant modification of the mentioned parameters was observed (Table 5) ; the comparisons over time between the two groups are shown in Figures 2-6 . In both groups, no modifications were observed in HDL cholesterol and echocardiographic parameters, except in the mean diastolic WT, mean systolic WT, and LVMI. These indices showed a significant decrease in both groups after 12 months of treatment; the reduction was maintained in the follow-up control (Tables 4, 5 ). However, the decrease in LVMI was significantly greater in the treated group ( Figure 7 ). In this group the percentage of patients with left ventricular hypertrophy was 46% before randomization and 17.2% (16 of 93) after 18 months of treatment (P Ͻ .0001), whereas in group II the percentage was 48% before randomization and 31.5% (29 of 92) after 18 months (P Ͻ .05). 
DISCUSSION
The present study shows that administration of transdermal 17␤-estradiol (50 g/day) in postmenopausal hypertensive women reduces total cholesterol, LDL cholesterol, fibrinogen, and fasting glucose plasma levels. A similar effect has been demonstrated in normotensive women who received oral estrogen/progestin treatment in the Postmenopausal Estrogen/ Progestin Interventions (PEPI) trial. 7 In our study population, after 6 months of treatment (and during all subsequent testing), triglyceride plasma levels decreased in the treated group, whereas HDL cholesterol did not change; these findings differ from the results of PEPI and other trials. 6, 7, 9 This may have resulted from the estrogen administration route, which determines different therapeutic effects. The transdermal route has two main advantages: natural estrogen is used and constant serum hormonal concentration is obtained, without hepatic involvement. 25 Oral administration uses conjugated-equine estrogens, which are absorbed in the intestine, exposing the liver to much higher concentrations of the hormone-the hepatic so-called "first pass effect"-which results in a bolus effect at each administration. 25 The oral route is associated with an increase in hepatic produced proteins, including lipoproteins (ie, VLDL and HDL), 26, 27 whereas the transdermal administration is not associ- ated with an increase in the plasma concentration of those proteins produced by the liver. 28 -30 Lipid and lipoprotein metabolism are differently affected by the route of administration of estrogen. Both types lower LDL cholesterol, the oral route increases HDL cholesterol (particularly the HDL 2 subfraction, which is the most protective), whereas the transdermal release has a somewhat lesser effect. 12, 31 Transdermal estradiol lowers triglycerides, whereas conjugated-equine estrogen increases them. 12, 31, 32 Total serum cholesterol, and LDL and HDL cholesterol levels independently predict cardiovascular death in women, 33, 34 and there are studies in which the inverse relation between HDL cholesterol and cardiovascular risk has been shown to be stronger in women. 35, 36 Triglyceride levels are also an important risk factor. In fact, in a multivariate analysis from the Framingham Study, elevated triglyceride levels were found to be an independent risk factor for heart disease in women and a better indicator than LDL cholesterol in predicting risk of coronary heart disease. 37 Recommendations from the National Cholesterol Education Program suggests a cautious approach in the use of lipid-lowering drugs for primary prevention in postmenopausal women; these guidelines recommend estrogen replacement therapy be tested first. 38 Our study indicates that estrogen replacement therapy can be individualized, recommending oral administration in the presence of low HDL cholesterol levels and transdermal administration in the presence of high triglyceride levels.
Insulin resistance is considered a relevant metabolic disturbance, leading to the development of coronary artery disease. 39 Estrogens improve glucose and insulin metabolism by reducing insulin resistance. 40 In our study, transdermal therapy lowers fasting glucose levels, a beneficial effect confirmed by other studies using transcutaneous estradiol. 13, 41 On the contrary, it has been reported that there is a bimodal effect of oral equine estrogens on insulin sensitivity, with an improvement at lower doses (ie, 0.625 mg/day) and a deterioration at higher doses. 42 Another important finding of our study is the behavior of the LVMI. In both groups, this parameter showed a significant reduction. The group receiving estrogen had a more significant decrease in LVMI compared with the group treated only with antihypertensive drugs. To our knowledge, no previous studies have analyzed this aspect. Left ventricular hypertrophy is a common feature of hypertensive cardiovascular disease. 43 The increase in LVM represents a pseudocompensation for the increase in pressure overload of the left ventricle and it is considered to be the most important independent risk factor for coronary heart disease in women. 44 No critical value has been detected to distinguish between compensatory and pathologic hypertrophy; the risk of cardiovascular sequelae increases progressively with the increase in LVM. 45 Echocardiographic investigations indicate that antihypertensive therapy can reverse LVM in hypertensive patients. 46 Mass regression leads to an improvement in left ventricular systolic and diastolic function, 47 an increase in coronary blood flow reserve, 48 and a reduction in arrhythmic episodes. 49 This suggests that a therapy that reduces LVM may improve the outcome in hypertensive patients. Drugs that have shown to be particularly effective in this situation are calcium antagonists, 50 -52 central and peripheral receptor blockers of the adrenergic system, 53, 54 and, especially, angiotensin converting enzyme (ACE) inhibitors. 55, 56 The results of our study clearly indicate that even estrogens play an important role in normalizing LVM. To explain this finding we can hypothesize several mechanisms. It is known that 17␤-estradiol has a powerful calcium-antagonist effect on both vascular smooth muscle cells and cardiac fibers. 57, 58 Furthermore, the role of 17␤-estradiol in inhibiting in vitro the vasoconstriction effect of angiotensin II 59 indicates clear ACE inhibitor properties in estrogens. This effect has been confirmed in a study on humans. Proudler et al highlighted a 20% reduction in plasma concentration of ACE after 6 months of treatment with transdermal 17␤-estradiol, 60 and Schunkert et al demonstrated that hormonal replacement therapy is related to a substantial suppression of serum renin levels. 61 Renin suppression was seen with either oral or transdermal estrogen administration, but the increase in angiotensinogen was limited to oral estrogen. 61 In conclusion, transdermal 17␤-estradiol, associated with antihypertensive therapy, may contribute to the reduction of the cardiovascular risk profile in hypertensive postmenopausal women.
A limitation of our study design concerns the absence of an arm treated with oral estrogen. A comparison between transdermal and oral administration may add more information regarding the effects of these different routes on biochemical and echocardiographic parameters. We decided to use transdermal estrogen replacement therapy first to improve patient compliance, especially in those taking oral multitherapy. Furthermore, little data exist regarding the effects of transdermal estrogen replacement therapy compared with oral administration. Further studies are needed to clarify these aspects.
